Clinical Trials

Phase 2 Active not recruiting

Anatomic Stage IV Breast Cancer AJCC v8

NCT04266249 2026-05-05

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

2,175 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT02705859 2026-04-13

Panther

26 enrolled

HER2 Positive Breast Cancer

NCT01526369 2025-05-09

TH V THL

Phase 3 Completed

75 enrolled

Breast Neoplasms

NCT03644186 2024-12-13

TOUCH

147 enrolled 11 charts

Breast Neoplasms

NCT00036868 2024-03-08

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

90 enrolled

Breast Neoplasms

NCT02649686 2023-08-04

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

15 enrolled

Breast Neoplasms

NCT03412643 2023-03-06

FB-12

Phase 2 Unknown

64 enrolled

Breast Neoplasms

NCT01597414 2022-11-17

Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

80 enrolled

Elderly Metastatic Breast Cancer Population

NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

105 enrolled 17 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01008150 2021-10-25

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

141 enrolled 16 charts

Breast Neoplasms

NCT01850628 2021-10-05

NSABP Biospecimen Discovery Project

Unknown

50 enrolled

Breast Neoplasms

NCT00004067 2021-04-29

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Phase 3 Completed

2,130 enrolled

Breast Neoplasms

NCT00625898 2020-09-10

BETH

Phase 3 Terminated

3,509 enrolled

Breast Neoplasms

NCT01548677 2019-03-13

TREAT-CTC

1,317 enrolled

Breast Neoplasms, Neoplastic Cells, Circulating

NCT01485926 2018-08-06

TCHL Phase II

120 enrolled

Breast Neoplasms

NCT00450892 2016-07-07

Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer

Phase 1/2 Completed

129 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00486668 2016-06-06

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Phase 3 Unknown

529 enrolled

Invasive Breast Cancer

NCT00968682 2014-12-31

CADY Study ICORG 08-01

Completed

480 enrolled

Breast Neoplasms, Cardiotoxicity

NCT01423123 2014-07-08

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

21 enrolled

Breast Neoplasms

NCT01367028 2014-05-13

ABCSG 32

100 enrolled

Breast Neoplasms

NCT00041067 2013-06-06

S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

76 enrolled 6 charts

Breast Neoplasms

NCT00068757 2012-09-12

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

23 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT00309556 2011-12-30

Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

Phase 3 Completed

536 enrolled

Breast Neoplasms

NCT00518583 2010-01-15

Phase II Study in Patients With Operable Breast Cancer

Phase 2 Unknown

30 enrolled